Amneal Pharmaceuticals, Inc. AMRX AvKARE — Gross Profit
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GrossProfit.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s avkare — gross profit.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s avkare — gross profit?
- Amneal Pharmaceuticals, Inc. (AMRX) reported avkare — gross profit of $39.08M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s avkare — gross profit changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s avkare — gross profit increased by 36.6% year-over-year, from $28.6M to $39.08M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s avkare — gross profit?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s avkare — gross profit has grown at a 22.1% compound annual growth rate (CAGR), from $66.14M to $146.79M.
- What does avkare — gross profit mean?
- Calculated as net revenue minus the cost of goods sold, representing the core profitability of the AvKARE segment before accounting for operating expenses. It serves as a key indicator of the segment's pricing power and the efficiency of its supply chain and manufacturing processes.